Emma Meesseman’s tremendous leap of faith to join the Liberty midseason is unlike anything we’ve seen in the WNBA.

In mHSPC, the UpFront PSMA and PSMAddition trials have demonstrated promising improvements in undetectable PSA rates and progression-free survival when LuPSMA was combined with standard therapies.

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 Results Release Conference Call and Live Webcast. [Operator Instructions].

Meanwhile, Novartis could be looking at another label expansion opportunity with Pluvicto. On Thursday, the company revealed that the phase 3 PSMAddition trial in metastatic hormone-sensitive ...

The company announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial on June 2, reporting that the trial met its primary endpoint. It demonstrated a ...

The company announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial on June 2, reporting that the trial met its primary endpoint.

PALM BEACH, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around ...

In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3.

Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus ...

Only Watching for Cancer? You’re Missing Alcohol's Real Harm Waiting on cancer as the endpoint? You’ll miss the real-time damage alcohol causes. Learn what to monitor instead: falls, cognitive ...

Matthew Rettig discusses the growing use of 177Lu-PSMA-617 post-VISION in mCRPC treatment. He highlights real-world data from the US Veterans Affairs system and genomic studies showing the impact of ...